Opioid Guide Not Included On FDA Agenda, Despite Congressional Push

FDA's anticipated final guidance on evaluation and labeling of abuse-deterrent opioids is absent from the recently released list of guidances the drug center plans to publish this year -- a notable omission considering Congress' year-end spending package withheld $20 million in salaries and expenses for the FDA commissioner's office pending finalization of the guidance. While FDA did not respond to inquiries about the guidance, HHS Secretary Sylvia Burwell told press Thursday (Jan. 15) that she hopes to work with Congress...

Subscriber Login

If you are a InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:

Enter your InsideHealthPolicy.com username.
Enter the password that accompanies your username.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.